Pfizer scored a big win on Thursday as a federal judge knocked out a large part of the multidistrict litigation over claims that it schemed to keep generic Lipitor off the market.
But some claims were left standing — namely that Pfizer violated antitrust law by paying off generic competitor Ranbaxy to delay entry under the guise of settling a patent suit, forcing the plaintiffs to pay as much as five times more for the brand-name drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
